Status: Recruiting
A Study to Assess Safety and Efficacy of SOT109 in Patients With Advanced Unresectable or Metastatic Colorectal Cancer
SOT109 is a special cancer medicine designed to find and kill certain cancer cells that carry a marker called CDH17, while causing less harm to healthy cells. The study consists of two parts, Part A and Part B. The goal of Part A is to collect information about SOT109, understand its effects, and see whether it is safe and well tolerated at different dose levels. Part B of the study collects information on which of the two selected safe dose levels chosen in Part A gives the best balance between benefit and risk.
Participants needed: 100
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: SOTIO Biotech a.s.Updated: Sep 21, 2026Locations: 3
Eligibility criteria
≥18 years of age on the day of signing the ICF [+33]
Received radiation therapy ≤14 days before day 1 of cycle 1 or not recovered to... [+15]